• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Chlamydia Infections - Pipeline Review, H2 2012 Product Image

Chlamydia Infections - Pipeline Review, H2 2012

  • ID: 2335189
  • November 2012
  • 53 pages
  • Global Markets Direct

Chlamydia Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Chlamydia Infections - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Chlamydia Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chlamydia Infections. Chlamydia Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Chlamydia Infections.
- A review of the Chlamydia Infections products under development by companies and universities/research READ MORE >

2
List of Tables 4
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Chlamydia Infections Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Chlamydia Infections 8
Chlamydia Infections Therapeutics under Development by Companies 10
Chlamydia Infections Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Discovery and Pre-Clinical Stage Products 15
Comparative Analysis 15
Chlamydia Infections Therapeutics – Products under Development by Companies 16
Chlamydia Infections Therapeutics – Products under Investigation by Universities/Institutes 17
Companies Involved in Chlamydia Infections Therapeutics Development 18
Emergent BioSolutions Inc. 18
CEL-SCI Corporation 19
Creative Antibiotics Sweden AB 20
Osel Inc. 21
Wittycell S.A.S. 22
Genetic Immunity, LLC 23
Genocea Biosciences, Inc. 24
Chlamydia Infections – Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
Chlamydia Vaccine - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
rifalazil - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
doxycycline - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ChlamyDerm Vaccine - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
MucoCept Platform - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Chlamydia Vaccine - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
INP-1750 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Human Liporale-Chlamydia Vaccine - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
WTCa Adjuvant - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
WTCb adjuvant - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
WTCn adjuvant - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Chlamydia Infections Therapeutics – Drug Profile Updates 46
Chlamydia Infections – Product Development Milestones 47
Featured News & Press Releases 47
Oct 04, 2012: Cempra Announces Positive Top-Line Results From Solithromycin Phase II Clinical Trial In Patients With Uncomplicated Urogenital Gonorrhea 47
Sep 27, 2010: TrioBiotics Pharma AG Announces Receipt Of Notice Of Allowance Of Patent For Rifalazil For Method Of Treatment And Prophylactic Use 47
Aug 09, 2010: TrioBiotics Pharma AG Announces New Strategic Direction To Focus On Rifalazil Development 48
Dec 15, 2009: Genocea Biosciences Awarded Grant For The Development Of Chlamydia Vaccines From The University Of Pittsburgh Medical Center’s Sexually Transmitted Infections Cooperative Research Center 49
Sep 13, 2007: Possible Vaccine Target For Chlamydia Identified 49
Mar 23, 2004: IMPAX Receives Final FDA Approval for Generic Version of Declomycin; Fifth ANDA Approval in 2004 50
Mar 23, 2004: IMPAX Receives Final FDA Approval for Generic Version of Declomycin; Fifth ANDA Approval in 2004 51
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 53
Disclaimer 53

List of Tables
Number of Products Under Development for Chlamydia Infections, H2 2012 8
Products under Development for Chlamydia Infections – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Late Stage Development, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 17
Emergent BioSolutions Inc., H2 2012 18
CEL-SCI Corporation, H2 2012 19
Creative Antibiotics Sweden AB, H2 2012 20
Osel Inc., H2 2012 21
Wittycell S.A.S., H2 2012 22
Genetic Immunity, LLC, H2 2012 23
Genocea Biosciences, Inc., H2 2012 24
Assessment by Monotherapy Products, H2 2012 25
Assessment by Stage and Route of Administration, H2 2012 27
Assessment by Stage and Molecule Type, H2 2012 29
Chlamydia Infections Therapeutics – Drug Profile Updates 46

List of Figures
Number of Products under Development for Chlamydia Infections, H2 2012 8
Products under Development for Chlamydia Infections – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 12
Late Stage Products, H2 2012 13
Mid Clinical Stage Products, H2 2012 14
Discovery and Pre-Clinical Stage Products, H2 2012 15
Assessment by Monotherapy Products, H2 2012 25
Assessment by Route of Administration, H2 2012 26
Assessment by Stage and Route of Administration, H2 2012 27
Assessment by Molecule Type, H2 2012 28
Assessment by Stage and Molecule Type, H2 2012 29

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos